Related references
Note: Only part of the references are listed.Histological Advantages of the Tumor Graft
Yoshimasa Akashi et al.
PANCREAS (2013)
Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft
M. Pia Morelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Manuel Hidalgo et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong et al.
CLINICAL CANCER RESEARCH (2010)
Targeting of drugs and nanoparticles to tumors
Erkki Ruoslahti et al.
JOURNAL OF CELL BIOLOGY (2010)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Kazuki N. Sugahara et al.
SCIENCE (2010)
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Kazuki N. Sugahara et al.
CANCER CELL (2009)
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Tambet Teesalu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer
Michael W. Mueller et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells
JS Wey et al.
BRITISH JOURNAL OF CANCER (2005)
Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract
DE Hansel et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Aberrant expression of neuropilin-1 and-2 in human pancreatic cancer cells
K Fukahi et al.
CLINICAL CANCER RESEARCH (2004)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors
M Li et al.
CANCER (2004)
Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma
AA Parikh et al.
CANCER (2003)
Share Paper
